Medical Device Global Market Access

On July 1, 2026, Brazil's ANVISA mandated the use of its new e-Notivisa system for all medical device adverse event reporting, replacing the legacy NOTIVISA platform. This episode details the critical changes, including the adoption of the International Medical Device Regulators Forum (IMDRF) adverse event coding, which aligns Brazil's technovigilance requirements with global standards. We discuss...

Brazil's ANVISA has implemented a more flexible amendment process for its regulatory reliance pathway for high-risk medical devices under Normative Instruction 290/2024. Effective June 2026, this change allows ANVISA to issue questions and request revisions for Class III and IV device submissions based on approvals from Comparable Foreign Regulatory Authorities (AREEs), rather than issuing an outr...

This episode covers the EU's new MDCG 2026-4 guidance, which transfers the responsibility for uploading the Summary of Safety and Clinical Performance (SSCP) from Notified Bodies to manufacturers. We discuss the impact on manufacturers of Class III and implantable devices, the key deadline of February 2027 for uploading the SSCP to EUDAMED, and the practical steps regulatory and quality teams must...

China's NMPA is rapidly approving innovative medical devices, creating a major opportunity for global manufacturers. A new report reveals that 40 innovative devices were approved in the first half of 2026, bringing the total to 431. With approval timelines now under six months, this episode breaks down the criteria for the innovative pathway, the benefits for manufacturers, and the practical steps...

Australia's Therapeutic Goods Administration (TGA) is launching its Unique Device Identification (UDI) system, with the first major compliance deadline set for July 1, 2026. This episode details the new requirements for sponsors of high-risk Class III and implantable Class IIb medical devices, explaining their obligations for submitting data to the new Australian UDI Database (AusUDID). We cover t...

On June 5, 2026, Japan's Pharmaceuticals and Medical Devices Agency (PMDA) issued a major update to its guidance for Software as a Medical Device (SaMD). This episode breaks down the three core changes: more stringent validation requirements for AI/ML algorithms, enhanced cybersecurity provisions aligned with global standards, and clearer classification rules for borderline products. We discuss th...

India's Central Drugs Standard Control Organisation (CDSCO) has published a draft amendment to shorten the approval timelines for medical device manufacturing licenses. This episode details the proposed reductions for Class B, C, and D devices, effective from the draft publication on June 28, 2024. We explore the rationale behind this move to improve regulatory efficiency and discuss the direct im...

This episode details the critical amendments to South Korea's Medical Device Act, which took effect on July 1, 2026. The host breaks down the two main changes from the Ministry of Food and Drug Safety (MFDS): the establishment of a stronger legal basis for the Quality Management System (QMS) Conformity Recognition Scheme and the implementation of stricter oversight for medical device distribution....

The FDA's June 6, 2026 draft guidance introduces significant new requirements for AI-enabled medical devices, focusing on total product lifecycle management. This episode breaks down the key changes, including stricter rules for algorithm transparency, data provenance, AI-specific risk management, and real-world performance monitoring. We discuss who is affected, the critical August 5, 2026 deadli...

Health Canada has finalized Phase 2 of its Medical Device Establishment Licence (MDEL) modernization, with new rules taking effect on December 14, 2026. This episode breaks down the three most significant changes impacting importers, distributors, and Class I manufacturers. We explore the new exemption for certain foreign distributors, the now-mandatory requirement for all MDEL holders to maintain...

Australia's TGA has amended medical device classification rule 5.5, effective July 1, 2024. The change removes materials of microbial and recombinant origin from the scope of the rule, which previously mandated a Class III classification. This will lead to the down-classification of certain devices, such as some dermal fillers or surgical meshes, likely to Class IIb. Sponsors of existing devices o...

Switzerland's swissdamed database becomes mandatory on July 1, 2026, for all medical devices and IVDs. This episode details the key deadlines, including the transition period until December 31, 2026, for existing devices, the scope of registration for all device classes, and the new annual fee structure based on UDI-DI counts. We provide practical steps for manufacturers to ensure compliance and m...

This episode details the UK MHRA's draft Medical Devices (Amendment) Regulations 2026, focusing on the proposed International Reliance pathway. We explore how this new framework aims to streamline market access in Great Britain for devices already approved by regulators in the US, Canada, or Australia. We cover the significance of the stakeholder survey deadline of June 19, 2026, the anticipated e...

Brazil's ANVISA has updated its review process for the regulatory reliance pathway under IN 290/2024. As of mid-June 2024, instead of rejecting submissions with minor issues, the agency will now issue requirement notices, allowing manufacturers to amend their applications. This episode explains how this change de-risks the submission process for Class III and IV medical devices that rely on approv...

This episode provides a detailed analysis of China's NMPA new post-market vigilance framework, released on June 12, 2026. We discuss the mandatory, risk-based system that introduces new obligations for foreign medical device manufacturers, including detailed requirements for trend reporting, Periodic Safety Update Reports (PSURs), and comprehensive vigilance planning. Learn about the immediate com...

On June 22, 2026, the Saudi Food and Drug Authority (SFDA) issued a landmark marketing authorization for an AI-powered mobile application that measures vital signs using a smartphone camera. We break down the technology behind this global first, remote photoplethysmography (rPPG), and explore the innovative regulatory pathways the SFDA used, including its Regulatory Sandbox. This episode details t...

The UK's MHRA announced on June 22, 2026, its intention to become a full member of the Medical Device Single Audit Program (MDSAP). This episode explores the significant impact of this decision on medical device manufacturers. We discuss how full membership will streamline the audit process, allowing a single quality management system audit to satisfy requirements for the UK, US, Canada, Australia...

Singapore's Health Sciences Authority (HSA) is reclassifying all COVID-19 in-vitro diagnostic (IVD) tests from the highest-risk Class D to Class C, effective June 2, 2026. This episode details the reasons for this regulatory shift as COVID-19 becomes endemic, explains the differences between Class C and Class D requirements, and outlines the practical impact on technical documentation, quality man...

India's drug regulator, the CDSCO, has proposed a new framework to allow hospitals to directly import a list of 80 high-end medical devices, such as MRI and CT scanners. This episode explores the potential policy shift, which aims to bypass the traditional licensed importer route to speed up access to advanced technology. We cover the implications for international manufacturers, the patient safet...

Health Canada issued a public advisory on June 16, 2026, warning that unauthorized soft-shelled hyperbaric chambers are illegal to sell, import, or advertise in Canada. This episode breaks down the specific health risks identified, the regulatory status of these devices, and the enforcement actions being taken. We provide practical compliance steps for manufacturers and distributors of wellness de...

Health Canada has finalized amended regulations for its Medical Device Establishment Licence (MDEL) framework, which come into force on December 14, 2026. This episode breaks down the critical changes, including the removal of the MDEL requirement for foreign distributors who sell through a licensed Canadian importer and the new obligation for Canadian MDEL holders to provide a complete list of th...

On June 17, 2026, the US FDA finalized a new Class II classification for radiological machine learning-based quantitative imaging software. This episode breaks down the new rule, explaining how the inclusion of a Predetermined Change Control Plan (PCCP) creates a more streamlined process for future algorithm updates. We detail the specific device types affected and the special controls manufacture...

Brazil's health agency, ANVISA, has announced its 2026-2027 regulatory agenda, which includes a significant revision to the rules for Software as a Medical Device (SaMD), RDC 657/2022. This episode explores the reasons for the update, the potential changes manufacturers can expect regarding AI/ML validation and cybersecurity, and the practical steps regulatory affairs and quality teams should take...

Singapore's Health Sciences Authority (HSA) released its updated guidance on medical device grouping, GN-12-1-R3, on June 2, 2026. This episode provides a detailed analysis of the key changes, including stricter criteria for device families, new requirements for systems and procedure packs, and the direct impact on manufacturers' registration strategies, costs, and timelines in Singapore. We outli...

Australia's Therapeutic Goods Administration (TGA) is enforcing its first major Unique Device Identification (UDI) deadline on July 1, 2026. This episode details the critical compliance steps for manufacturers and sponsors of Class III and Class IIb implantable medical devices. We cover the dual requirements for applying a UDI carrier to labels and submitting comprehensive device data to the Austr...